Publications

Found 23 results
Filters: First Letter Of Last Name is P  [Clear All Filters]
2025
Tang X-H, Pesola G, Chen Q, Miller D, Nagy LE, McMullen MR, Schwartz RE, Tsoy S, Lim C, Chikara S et al..  2025.  Ethanol causes rapid decreases in the hepatic retinoid levels shaping the early steps of alcohol-associated liver disease.. Alcohol Clin Exp Res (Hoboken).
2024
Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.
Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.
2023
Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.
2022
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.
Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)
2021
Melis M, Tang X-H, Attarwala N, Chen Q, Prishker C, Qin L, Gross SS, Gudas LJ, Trasino SE.  2021.  A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes.. Biofactors.
2019
Melis M, Tang X-H, Trasino SE, Patel VM, Stummer DJ, Jessurun J, Gudas LJ.  2019.  Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease.. PLoS One. 14(1):e0211071.
van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.
van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.
2018
Sureshbabu A, Patino E, Ma KC, Laursen K, Finkelsztein EJ, Akchurin O, Muthukumar T, Ryter SW, Gudas L, Choi AMK et al..  2018.  RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.. JCI Insight. 3(11)
2015
Williams RM, Shah J, Ng BD, Minton DR, Gudas LJ, Park CY, Heller DA.  2015.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.. Nano Lett. 15(4):2358-64.
Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.  2015.  MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.. Oncotarget. 6(34):35710-25.
2013
Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, Mongan NP, Gudas LJ, Persson JL.  2013.  CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.. Cell Cycle. 12(8):1251-66.
Pérez RJ, Benoit YD, Gudas LJ.  2013.  Deletion of retinoic acid receptor β (RARβ) impairs pancreatic endocrine differentiation.. Exp Cell Res. 319(14):2196-204.
Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.
Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.
Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JLiao, Gudas LJ, Mongan NP.  2013.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.. Mol Oncol. 7(3):555-66.
2012
Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.  2012.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).. Int J Oncol. 40(1):5-12.
2007
Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.
2002
Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.
Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.